1. Academic Validation
  2. Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor

Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor

  • Nat Biotechnol. 2024 Dec 11. doi: 10.1038/s41587-024-02503-w.
Yanyun Fu 1 2 3 4 Xiao Ding 1 2 4 Man Zhang 1 2 3 Chunlei Feng 1 2 Ziqi Yan 1 2 Feng Wang 1 2 Jianyu Xu 1 2 Xiaoxia Lin 1 2 Xiaoyu Ding 1 2 Ling Wang 1 2 Yaya Fan 1 2 Taotao Li 1 2 Yushu Yin 1 2 Xing Liang 1 2 Chenxi Xu 1 2 Shan Chen 1 2 Fadi E Pulous 1 5 David Gennert 1 5 Frank W Pun 1 3 Petrina Kamya 1 6 Feng Ren 1 2 3 4 Alex Aliper 1 4 Alex Zhavoronkov 7 8 9 10
Affiliations

Affiliations

  • 1 Insilico Medicine US, Inc., Boston, MA, USA.
  • 2 Insilico Medicine Shanghai, Ltd., Shanghai, China.
  • 3 Insilico Medicine Hong Kong, Ltd., Hong Kong, China.
  • 4 Insilico Medicine AI, Ltd., Abu Dhabi, UAE.
  • 5 Insilico Medicine US, Inc., New York, NY, USA.
  • 6 Insilico Medicine Canada, Inc., Montréal, Québec, Canada.
  • 7 Insilico Medicine US, Inc., Boston, MA, USA. alex@insilico.com.
  • 8 Insilico Medicine Shanghai, Ltd., Shanghai, China. alex@insilico.com.
  • 9 Insilico Medicine Hong Kong, Ltd., Hong Kong, China. alex@insilico.com.
  • 10 Insilico Medicine US, Inc., New York, NY, USA. alex@insilico.com.
Abstract

Hypoxia-inducible factor prolyl hydroxylase (PHD) inhibitors have been approved for treating renal anemia yet have failed clinical testing for inflammatory bowel disease because of a lack of efficacy. Here we used a multimodel multimodal generative artificial intelligence platform to design an orally gut-restricted selective PHD1 and PHD2 inhibitor that exhibits favorable safety and pharmacokinetic profiles in preclinical studies. ISM012-042 restores intestinal barrier function and alleviates gut inflammation in multiple experimental colitis models.

Figures
Products